Archives - December, 2005

. . . New Oil rigs, new oil properties - Tri-Valley Corporation
(Amex: TIV) has purchased the oil producing properties of Brea Oil Company in western Kern County, California. Tri-Valley has also received its first purchased production rig. The Company expects a second purchased production rig which can drill to 8,000 feet to be received in February, 2006, in time to drill new wells on its producing properties. In addition, the company is negotiating purchase of a third rig. The new rigs are expected to service Tri-Valley's growing inventory of wells.

. . . Dopamine breakthrough - Brain Storm Cell Therapetics (OTCBB:BCLI) has come up with a unique process for differentiating bone marrow stem cells into neural-like cells capable of secreting dopamine, the substance that is depleted in Parkinson's patients. A follow-up preclinical study on animals demonstrated a more than fifty percent reduction in the animals' rotational movement, seven months after implantation.

. . . Better digital video - Splinex Technology (OTCBB:SPLX), a provider of visualization software and technology, has signed a letter of intent to acquire EnerSoft. The acquisition will give Splinex access to EnerSoft's technologies which improve the quality of video for high definition television (HDTV), the Internet, mobile phones, digital cameras and other applications. Some of EnerSoft's technologies are incorporated into the international standard for multimedia and compression known as MPEG-4.

. . . New early breast cancer detection - Matritech (Amex: MZT), a developer of protein-based diagnostic products for the early detection of cancer, has discovered the existence of certain proteins (NMP66) in the blood of breast cancer patients that are generally not present in the blood of women without detectable breast malignancy. The Company is continuing to refine the methods for detecting the NMP66 complex in the blood of women with breast cancer.

. . . MS study - The recent death of Richard Pryor with footage of his long struggle with MS has put new focus on the devastating disease and the search for more effective treatment. The Quigley Corporation (Nasdaq: QGLY) recently announced results of a mouse multiple sclerosis model (EAE) study which has shown that the QR-442, a naturally derived compound, was found to delay onset of disease as well as considerably lowering severity. Results showed that mice treated with QR-442 had a delayed onset of the disease and severity was considerably lower especially in animals receiving several doses of the compound. Currently there is no cure for MS and an estimated 3 million people live with it worldwide.

. . . Solar funding - XsunX, (OTCBB:XSNX) a solar technology company, received $5,000,000 in financing from Cornell Capital Partners to help drive the continued development and growth of the Company. XsunsX has developed a technology called Power Glass(tm) - a thin layer of film glazing that allows glass windows to produce electricity from the power of the sun. When XsunX films are exposed to light, the light energy is converted into electrical energy for use as a power source.

. . . Acquiring new gold mines - Vista Gold Corp. (Amex: VGZ; TSX) has acquired all of the outstanding shares of F.W. Lewis, Inc., the assets of which include 55 mineral properties in Nevada and Colorado. The 53 properties to be retained by Vista include a total of 9,280 acres of patented and 11,616 acres of unpatented mineral claims, the majority having gold, silver or copper discoveries or old mines located on the properties. Vista Gold evaluates and acquires gold projects with defined gold resources

. . . 30% increase in mineral reserves - Taseko Mines Limited (TSX VENTURE:TKO; AMEX:TGB) announced a 30% increase in mineral reserves at the Gibraltar copper-molybdenum mine. The Gibraltar mine is located near the City of Williams Lake in south-central British Columbia. Proven and probable mineral reserves, as of September 30, 2005, have increased from 149 million tons to 194 million tons. Under present operating conditions, the additional reserves increase the mine life to 15.5 years.

. . . New atrial study - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) initiated a Phase 2a pilot study of oral RSD1235 for the prevention of recurrence of atrial fibrillation.The study will measure the safety and efficacy of oral RSD1235 in patients at risk of recurrent atrial fibrillation. About 2.2 million Americans experience atrial fibrillation, which occurs when the heart's two small upper chambers (the atria) quiver instead of beating properly. It can lead to a blot clot in the atria and eventually a stroke. It is expected that the majority of patients enrolled will have experienced atrial fibrillation for greater than 30 days and less than 180 days in duration. The study will enroll 180 patients across 75 centres in Canada, U.S. and Europe.

Cardiome Pharma Corp. is a cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at congestive heart failure. Cardiome recently completed the acquisition of Artesian Therapeutics, a U.S. biopharmaceutical company developing bi-functional small-molecule drugs for the treatment of cardiovascular disease.

. . . Night vision sees record sales - Extreme CCTV (TSX:EXC.TO), a maker of active-infrared night vision surveillance equipment, reported record quarterly and annual revenues in its financial results for the three and twelve month periods ended September 30, 2005. For the fiscal fourth quarter ended September 30, 2005, Extreme reported revenues of $6.5 million, a 19% increase over revenues of $5.5 million for the quarter ended September 30, 2004. Gross margin increased to 49.2% of sales from 45.2%.

The company's strategy is to expand into vertical markets in Defense, Department of Homeland Security, Intelligent Transportation Systems (ITS), policing and parking enforcement, and integrate with other technologies for detection, delivery and intelligent analysis of potential security threats.